RxDoctor Payments Data

Sylvia Gisi, MD

Family Medicine · Temecula, CANPI 1720052541

Payments from drug & device makers

$5,424in general payments, 2019–2025

Across 230 payments — averaging $23.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • AbbVie$850
  • GSK$318
  • Abbott$213
  • Merck$208
  • Johnson & Johnson$182
  • plus $2K from 42 others

What the payments were for

  • Food & beverage$5,38399%
  • Education$411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,424 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$126,909
Medicare patients
218
Services billed
1,137

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JanuviaSitagliptin Phosphate50$58,914
OzempicSemaglutide37$44,481
MounjaroTirzepatide21$36,740
FarxigaDapagliflozin Propanediol30$24,693
XareltoRivaroxaban23$22,394
EliquisApixaban23$18,240
MyrbetriqMirabegron14$12,069
Spiriva RespimatTiotropium Bromide17$8,658
VesicareSolifenacin Succinate11$4,116
Levothyroxine Sodium394$3,484
SynthroidLevothyroxine Sodium60$3,265
Qvar RedihalerBeclomethasone Dipropionate11$2,963
Lantus SolostarInsulin Glargine,hum.Rec.Anlog17$2,457
Atorvastatin Calcium211$1,946
Ibandronate Sodium36$1,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$208$58,91450 claims
Novo NordiskOzempic$36$44,48137 claims
Lilly USA, LLCMounjaro$139$36,74021 claims
AstraZenecaFarxiga$1,429$24,69330 claims
Johnson & JohnsonXarelto$182$22,39423 claims
PfizerEliquis$74$18,24023 claims
Astellas Pharma US IncMyrbetriq, Vesicare$58$16,18525 claims
Boehringer IngelheimSpiriva Respimat$58$8,65817 claims
AbbVieSynthroid$850$3,26560 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.

Other family medicine in Temecula

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →